POCTech Corporation

What POCTech Corporation does

POCTech Corporation (浙江凯立特医疗器械有限公司) is a privately held Chinese medical device company founded in 2010 in Huzhou, Zhejiang Province, that develops, manufactures, and markets continuous glucose monitoring (CGM) systems for diabetes patients and healthcare providers. The company is led by founder Dr. Zhang Yanan, who previously led the development of the first artificial pancreas glucose sensor and the CGMSGold dynamic blood glucose product at Medtronic. Its core platform is a proprietary four-electrode biosensor technology in which multiple electrodes are synthesized on a single ultra-fine (0.3mm) flexible substrate; the four electrodes monitor background and interference signals in real time and apply real-time corrections to the glucose signal, a design the company positions against single- or dual-electrode competitors. The flagship product is the CT-100 CGM system, which provides continuous glucose readings every three minutes for seven days with once-daily calibration, transmits data over BLE Bluetooth to a smartphone app and companion cloud-based diabetes management platform, and has demonstrated clinical MARD of 9.61% versus finger blood and 8.67% versus venous blood. A second-generation CT-2 CGM system has been added to the portfolio. POCTech has secured CE certification (April 2016) and NMPA/CFDA registration (February 2021), and has distribution reach in 13 countries through an exclusive partnership with Ascensia Diabetes Care, with options for further geographic expansion.

The company operates a dual-channel go-to-market: direct enterprise sales to hospitals and clinics in China, combined with the Ascensia exclusive distributor arrangement internationally. Revenue is generated primarily through hardware sales of the CGM systems and disposable sensors/transmitters; specific pricing is not publicly disclosed. POCTech has raised approximately 100 million RMB (~$14.5M USD) across funding rounds, including a 2014 Series A from Legend Capital and a 2017 Series B co-led by Yuan Sheng VC and Tasly Health Industry Fund with participation from Tonghua Dongbao, a leading domestic insulin manufacturer. The company has positioned itself within a broader diabetes ecosystem through a strategic alliance with Kailian Medical (insulin pumps) targeting an integrated CGM-plus-pump pathway toward future artificial pancreas applications. Customers are Type 1, Type 2, and gestational diabetes patients, supplemented by hospital and clinical use cases for treatment optimization. The company reports headcount in the 1-10 range.

Name

POCTech Corporation

Legal name

浙江凯立特医疗器械有限公司

Website

https://poctechcorp.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

1–10 employees

Short description

POCTech Corporation is a Chinese medical device company founded in 2010 that develops continuous glucose monitoring (CGM) systems using proprietary four-electrode biosensor technology. It serves diabetes patients and healthcare providers through the CT-100 and CT-2 CGM product lines via direct sales in China and exclusive distribution with Ascensia Diabetes Care internationally.

Ownership category

akta.pro rank

Product category

Continuous Glucose Monitoring Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro industry

PRIMARYHLAHAHAA

Continuous Glucose Monitoring (CGM) Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)

SECONDARYHLACAPAK

Remote Diagnostics & Point-of-Care (Connected Testing, Home Lab Devices)

Healthcare & Life Sciences/Digital Health & Health IT/Healthcare IoT & Remote Patient Monitoring

Keywords

• Continuous glucose monitoring
• Biosensor medical devices
• Diabetes management systems
• Glucose sensor technology
• Wearable medical devices

Headquarters

HQ city

Huzhou

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. CGM Device Sales: Sale of CT-100 continuous glucose monitoring systems and related sensors/transmitters to healthcare providers and patients.
2. International Distribution: Revenue through distribution partnerships with Ascensia Diabetes Care covering 13 countries globally.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

POCTech Corporation (浙江凯立特医疗器械有限公司) develops, manufactures, and markets continuous glucose monitoring (CGM) systems for diabetes management. Its products center on a proprietary four-electrode biosensor technology that delivers real-time glucose readings via Bluetooth to a smartphone app and cloud-based diabetes management platform, with sensors designed for 7-day continuous wear on the arm or abdomen. The portfolio includes the first-generation CT-100 (CE-certified in 2016, CFDA-registered in 2021) and the CT2 second-generation CGM system.

Product overview

POCTech Corporation (浙江凯立特医疗器械有限公司) offers a focused portfolio of continuous glucose monitoring (CGM) products centered on its CT-100 and CT2 CGM systems. These products share a core proprietary four-electrode biosensor technology platform and are distributed with BLE Bluetooth connectivity, a smartphone app, and a cloud-based diabetes management platform. The portfolio spans the CT-100 system (first generation, CE-certified 2016, CFDA-registered 2021) and the CT2 system (second generation). The company does not currently offer a public API, AI/ML capabilities, or documented third-party software integrations beyond its own app and cloud ecosystem.

Differentiator

Problem solved

Functional benefit

Brands

• CT-100: Continuous glucose monitoring system with four-electrode sensor technology, BLE connectivity, and 7-day wear capability.

Products and services

• CT-100 Continuous Glucose Monitoring System A real-time continuous glucose monitoring system featuring a proprietary four-electrode micro flexible sensor (0.3mm) worn on the arm or abdomen for 7-day continuous monitoring with once-daily calibration. Glucose readings are transmitted via BLE Bluetooth to a smartphone app and a cloud-based diabetes management platform, delivering readings every 3 minutes (3,360 data points per wear cycle). Sold to healthcare providers and patients through distribution channels including Ascensia Diabetes Care for international markets.
• CT2 Continuous Glucose Monitoring System Second-generation continuous glucose monitoring system extending POCTech's CGM product line. Shares the core proprietary four-electrode biosensor technology platform with the CT-100 system.

Quantifiable outcome

• MARD of 9.61% compared to finger blood, 8.67% compared to venous blood (clinical study, 80 cases, 2 hospitals)
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Ascensia Diabetes CarecoreChannel Partner/ Reseller/ Distributor · 8 January 2019Strategic distribution partnership where Ascensia appointed as exclusive distributor for POCTech's CGM products in 13 countries, with preferential rights for other countries. Ascensia will market and sell the CE-certified CT-100B CGM system starting mid-2019. Joint development agreement also established to co-develop next-generation CGM products combining both companies' sensor technologies.
• Kailian Medical (凯联医疗)coreStrategic or Co-development Partner · 1 January 2014Strategic partnership to create diabetes management ecosystem. Kailian Medical focuses on micro-dose drug precision infusion systems (insulin pumps) that, combined with POCTech's CGM, enables future artificial pancreas development. Joint investments made by Yuansheng and Tasly in both companies.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Dexcom: Global CGM market leader with G6/G7 systems; directly comparable real-time CGM with smartphone connectivity. The benchmark POCTech cites for MARD accuracy (~10%).
• Ascensia Diabetes Care: POCTech's exclusive distribution partner and also a diabetes monitoring peer with CONTOUR BGM franchise; comparable BGM/CGM product scope and overlapping customer base.

Broad incumbents

• Abbott Diabetes Care (FreeStyle Libre): Largest CGM installed base globally with FreeStyle Libre 2/3 flash glucose monitors; broader diabetes division including BGM and consumer health, offering overlapping but more comprehensive capabilities than POCTech.
• Medtronic Diabetes: POCTech founder previously led CGM development at Medtronic (CGMS Gold). Medtronic's Guardian/Envision CGM plus insulin pumps overlap directly with POCTech's CGM-plus-Kailian ecosystem play.
• Roche Diabetes Care: Global incumbent in BGM (Accu-Chek) with growing CGM presence; established hospital and consumer channels comparable to those POCTech is building via its own and Ascensia's networks.

Emerging players

• Senseonics: U.S. implantable long-term CGM (Eversense) targeting similar accuracy and patient-compliance narratives; comparable stage and scale to POCTech in competing against Dexcom/Abbott.
• Aikang Medical (爱康医疗): Emerging Chinese medical device maker with CGM and insulin pump development; comparable to POCTech in ecosystem ambitions (monitoring + therapy) and in competing for Chinese diabetes share.

Regional players

• MicroTech Medical (微泰医疗): Chinese CGM/diabetes device competitor with AiDEX CGM; the most direct domestic head-to-head against POCTech in the China CGM market after CFDA approval.
• Sinocare (三诺生物): China's dominant blood glucose monitoring (BGM) leader expanding into CGM; comparable Chinese diabetes monitoring/diagnostics focus and similar hospital-channel GTM.
• Yuwell Medical (鱼跃医疗): Large Chinese home medical device manufacturer with diabetes monitoring ambitions; broader product portfolio but overlapping diabetes and connected-health positioning with POCTech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about POCTech Corporation